DOREMI

Clinical Question

In patients with cardiogenic shock, does milrinone as compared with dobutamine improve the composite outcome of in-hospital death, resuscitated cardiac arrest, receipt of cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, cerebrovascular event or renal replacement therapy?

Critical Appraisal

Key findings

Primary outcome: no significant difference in the composite of in-hospital death,
resuscitated cardiac arrest, receipt of cardiac transplant or mechanical
support, non-fatal myocardial infarcation, cerebrovascular event or renal
replacement therapy. Comparing milrinone vs dobutamine group 49% vs 54% (RR 0.9, 95% CI 0.69 – 1.19, p = 0.47)

Critique

In patients with cardiogenic shock, no significant difference between
milrinone and dobutamine was found with respect to the primary composite
outcome or important secondary outcomes

Outcome Results

Not recorded